What is isatuximab (Isatuximab-irfc)?

Isatuximab (Isatuximab-irfc) is a drug that is part of monoclonal antibody therapy and is used to treat multiple myeloma (Multiple Myeloma, MM). The drug works by targeting a specific molecular target on the surface of multiple myeloma cells called CD38.

Multiple myeloma is a malignant tumor that originates from plasma cells in the bone marrow, which are the cells that are normally responsible for producing antibodies. In patients with multiple myeloma, an abnormal increase in malignant plasma cells results in limited production of normal blood cells in the bone marrow, leading to symptoms such as bone destruction, anemia, and impaired immune function.

Isatuximab works by binding to and inhibiting the CD38 molecule on the surface of multiple myeloma cells to exert its efficacy. The mechanism of this drug includes the following aspects:

1.Inhibit cell proliferation: Isatuximab can prevent the growth and division of multiple myeloma cells, thereby reducing the tumor burden.

2.Induce cell apoptosis: It can promote multiple myeloma cells to enter a state of apoptosis, which is a process of cell self-destruction and helps reduce the number of cancer cells.

3.Stimulate the immune system: Isatuximab can also enhance the activity of the immune system, especially natural killer cells (NK cells), making them more effective in attacking cancer cells.

Isatuximab is often combined with other anticancer drugs and treatments to enhance the effectiveness of the treatment. It has shown potential in clinical trials to extend survival and improve the quality of life of patients with multiple myeloma. However, like all medications, it may cause side effects, including infection, anemia, thrombocytopenia, nausea, vomiting, and fatigue.